We previously demonstrated that the transcription factor NF-E2-related factor2 (Nrf2), expressed abundantly in non-small-cell lung cancer (NSCLC) cells, plays a pivotal role in the proliferation and chemoresistance of NSCLC. Here we show that Nrf2-mediated NSCLC cell proliferation is dually regulated by epidermal growth factor receptor (EGFR) signaling and an Nrf2 repressor protein Keap1 (Kelch-like ECH-associated protein-1). NSCLC cells expressing wild-type EGFR and Keap1 genes show enhanced proliferation on stimulation with EGFR ligand under non-stress conditions. Exposure to cigarette smoke extract (CSE) enhanced cell proliferation by modification of the Nrf2/Keap1 interaction. Although EGFR-tyrosine kinase inhibitor (TKI) inhibited the proliferation of these cells, exposure to CSE attenuated its efficacy. In NSCLC cells with Keap1 gene mutations, Nrf2 was constitutively activated owing to dysfunction of Keap1 and cells proliferated independently of EGFR signaling. Furthermore, EGFR-TKI was unable to inhibit their proliferation. In NSCLC cells with EGFR gene mutations, Nrf2 was constitutively activated by EGFR signaling. In these cells, proliferation was largely dependent on the EGFR signaling pathway. Although these cells were highly sensitive to EGFR-TKI, exposure to CSE or knockdown of Keap1 mRNA reduced sensitivity to EGFR-TKI. We found a case of NSCLC showing resistance to EGFR-TKI despite having EGFR-TKI-sensitive EGFR gene mutation because of dysfunctional mutation in Keap1 gene. Results indicate that oxidative stress reduces the anticancer effects of EGFR-TKI in wild-type Keap1 NSCLC cells. Analysis of Keap1 dysfunction may become a novel molecular marker to predict resistance to EGFR-TKI in NSCLC cells having EGFR-TKI-sensitive EGFR mutations. Finally, as the downstream molecule of both EGFR and Keap1 signaling, Nrf2 is an important molecular target for the treatment of NSCLC, where cells have mutations in EGFR, KRAS or Keap1 genes.
INTRODUCTION
Lung cancer is the leading cause of cancer-related death in developed countries. 1 Despite decades of intensive efforts to combat this disease, the prognosis of lung cancer remains unfavorable and is especially poor in advanced non-small-cell lung cancer (NSCLC) cases.
NSCLC cells exploit several molecules for their survival, growth and drug resistance. The transcription factor NF-E2-related factor2 (Nrf2) is a cap 'n' collar basic leucine-zipper transcription factor originally identified as a pivotal factor for cell protection from oxidative and electrophilic insults. 2 Interestingly, Nrf2 is highly expressed in cancer cells, especially NSCLC cells. 3, 4 We have recently demonstrated that Nrf2 causes cell proliferation and resistance to anticancer drugs by transactivating its target genes, including various detoxification enzymes, glutathione-related enzymes, drug efflux pumps and cell-cycle regulatory proteins. 5, 6 The activation of Nrf2 is mainly regulated by its inhibitory protein Kelch-like ECH-associated protein-1 (Keap1). Under resting conditions in normal cells, Nrf2 is retained in the cytoplasm by Keap1 and is maintained at a reduced level by the Keap1-dependent ubiquitination and proteasomal degradation systems. 7, 8 Upon exposure to oxidative stress or xenobiotic stress, Keap1-dependent ubiquitin ligase activity is inhibited and Nrf2 can translocate to the nucleus, where it forms a heterodimer with small Maf proteins and binds to a consensus sequence called the antioxidant response element. The constitutive activation of Nrf2 due to dysfunctional Keap1 gene mutations is observed in patients with NSCLC. 3, 4, 9 Beside Keap1, activation of Nrf2 is positively regulated through activation of the extracellular regulated kinase (ERK) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathways. 10 In cancer cells, these pathways are often activated via epidermal growth factor receptor (EGFR) signaling pathways. EGFR is expressed abundantly in NSCLC cells, and cell proliferation and survival are largely mediated by EGFR signaling in these cells. 11 However, the relationship between Nrf2 activation and EGFR signaling in NSCLC cells has not been elucidated before now. In this study, we therefore investigate the regulation of EGFR and Keap1 in Nrf2-mediated cancer cell proliferation using three different NSCLC cell lines. We further demonstrate a case of NSCLC showing resistance to EGFR-tyrosine kinase inhibitor (TKI) in the metastatic brain lesion due to a mutation in EGFR gene.
RESULTS
EGFR signaling activates Nrf2 and enhances Nrf2-mediated cell proliferation in both Keap1 and EGFR gene wild-type NSCLC cells We first evaluated the Keap1, EGFR and Nrf2 genes for mutations in three different NSCLC cell lines, NCI-H292 cells, PC-9 cells and A549 cells (Table 1) . By direct sequencing analysis, A549 cells were found to have a point mutation in the Kelch domain of Keap1, and a wild-type EGFR gene. In contrast, PC-9 cells were found to have a deletion mutation in the EGFR gene (del E746-A750) located in exon 19 , resulting in constitutive activation of the EGFR signaling pathway, while no mutation was detected in the Keap1 gene. Both Keap1 and EGFR genes were wild type in NCI-H292 cells. No mutation was detected in the Nrf2 gene in any of the cell lines.
To clarify the effects of EGFR signaling on the activation of Nrf2 in these NSCLC cells, they were treated with EGF, an EGFR ligand. Western blot analysis revealed that low amounts of Nrf2 were detected in the nuclear fraction of NCI-H292 cells in resting conditions, but this was substantially increased following stimulation with EGF ( Figure 1a ). On the other hand, Nrf2 was constitutively activated in resting PC-9 cells and A549 cells, and the degree of Nrf2 nuclear translocation was not altered by stimulation with EGF ( Figure 1a) . Western blot analysis also revealed that Keap1 protein level was not affected by EGF stimulation in any of the cell lines (Figure 1a ). Immunohistochemistry also revealed that Nrf2 was localized predominantly in the nuclei of NCI-H292 cells following stimulation with EGF, whereas Nrf2-positive cells were scarcely seen in resting condition (Figure 1b) . Nrf2 was constitutively expressed on the nuclei of PC-9 cells and A549 cells in unstimulating condition, and the degree of the immunoreactivity was not altered by stimulation with EGF (Figure 1b) . Keap1 was constitutively expressed in the cytoplasm, and neither its expression nor cellular localization was altered by stimulation with EGF in any of the cell lines (Figure 1b) .
We then assessed whether Nrf2 acts as a downstream molecule of EGFR signaling for cancer cell proliferation using RNA interference technique. In NCI-H292 cells, treatment with EGF significantly increased cell proliferation, compared with untreated controls (Figure 1c ). This was significantly inhibited by treatment with The expression and localization of Nrf2 was also evaluated by immunocytochemistry. Cells were fixed and immunostained using anti-Nrf2 and anti-Keap1 antibodies. Diaminobenzidine was used as a chromogen. (c) The relationship between EGFR signaling and Nrf2 to cancer cell proliferation was evaluated by using RNA interference technique. NCI-H292 cells, PC-9 cells and A549 cells were plated in 100 mm dishes, transfected with Nrf2-siRNA or NC-siRNA, and cultured in the presence or absence of 50 ng/ml of EGF (n ¼ 8 in each group). Viable cells were quantified every 24 h using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. *Significantly different between the NC-siRNA-and EGF-treated groups and other groups.
#
Significantly different between the NC-siRNA-and Nrf2-siRNA-treated groups.
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Nrf2-small interfering RNA (siRNA) in both EGF-stimulated and -nonstimulated NCI-H292 cells (Figure 1c ). In contrast, treatment with EGF did not affect the proliferation of PC-9 cells and A549 cells (Figure 1c ). Treatment with siRNAs directed against human Nrf2 (Nrf2-siRNA), however, inhibited the proliferation of these cells in both EGF-stimulated and -non-stimulated conditions ( Figure 1c ). (Figure 2a ). Nuclear translocation of Nrf2 was also observed after stimulation with EGF ( Figure 2a ). However, Keap1 levels were not affected by stimulation with EGF in these cells (Figure 2a ). To clarify which signaling pathways contributed to the activation of Nrf2, NCI-H292 cells were treated with U0126, an MEK1/2 inhibitor, or LY294002, a PI3K inhibitor. A concentration-dependent inhibition of EGFR ligand-mediated activation of Nrf2 was observed following treatment with U0126, but not with LY294002 ( Figure 2b ). EGFR ligand-mediated activation of Nrf2 was also inhibited by treatment with AG1478, an EGFR-TKI (Figure 2b ). In contrast, Keap1 levels were not affected by treatment with either U0126, LY294002 or AG1478 in these cells (Figure 2b ).
We also assessed the effect of blockade of EGFR signaling on Nrf2 activation in all three cell lines. As stated above, activation of Nrf2 was inhibited by treatment with AG1478 in NCI-H292 cells and PC-9 cells (Figure 2c ). However, Nrf2 was constitutively activated in A549 cells, and this activation was not inhibited by AG1478 (Figure 2c) .
We then assessed the influence of the inhibition of EGFR signaling pathways on NSCLC cell proliferation. EGF-stimulated NCI-H292 cell proliferation was significantly inhibited by treatment with AG1478 or by U0126 (Figure 2d ). PC-9 cell proliferation was markedly inhibited by treatment with AG1478 or with U0126 irrespective of EGF stimulation (Figure 2d ). Treatment with LY294002 partially inhibited the proliferation of PC-9 cells, implying that PI3K/Akt is not the predominant pathway controlling PC-9 cell proliferation. The proliferation of A549 cells was not affected by treatment with AG1478 or with LY294002 irrespective of EGF stimulation (Figure 2d ). The proliferation of A549 cells, however, was partially decreased following treatment with U0126, implying a partial contribution by the Ras/ERK signaling to the proliferation of A549 cells (Figure 2d ).
Oxidative stress activates Nrf2 and enhances cell proliferation in Keap1 and EGFR wild-type NSCLC cells Previous studies have demonstrated that Nrf2 activation following stimulation with oxidative stress, such as cigarette smoke exposure, is regulated through the stress sensor protein Keap1. To assess the effects of oxidative stress on cancer cell proliferation, the cells were exposed to various concentrations of cigarette smoke extract (CSE). Cell proliferation was significantly enhanced (1.5-fold) after incubation with low-dose CSE (B0.1%) in NCI-H292 cells, compared with the CSE-untreated control. On the other hand, exposure to CSE did not affect the growth of PC-9 cells and A549 cells at the range of 0 --0.1% (Figure 3a ). High-dose CSE (5%) caused cell damage and inhibited the proliferation of NCI-H292 cells and PC-9 cells. The proliferation of A549 cells was also inhibited by 5% CSE (Figure 3a) .
To assess the relationship between oxidative stress and EGFR signaling on cancer cell proliferation, cells were co-treated with CSE and EGF. In NCI-H292 cells, cell proliferation was additively increased by treatment with CSE and EGF ( Figure 3b ). Co-treatment with CSE and EGF did not affect the proliferation of PC-9 cells or A549 cells (Figure 3b ). We then assessed the influence of oxidative stress on the anticancer effect of EGFR-TKI. Exposure to CSE reduced NCI-H292 cell sensitivity to AG1478: cell proliferation was significantly higher in AG1478-treated NCI-H292 cells exposed to CSE than in those of unexposed controls (Figure 3c ). Cell proliferation was also greater in AG1478-treated PC-9 cells exposed to CSE than in those of unexposed controls, regardless of EGF stimulation (Figure 3c ). Exposure to CSE did not affect the sensitivity of A549 cells to AG1478 (Figure 3c ).
We further assessed the relationship between CSE exposure and EGFR signaling on the activation of Nrf2 in these cells. Nrf2 activation was enhanced by CSE exposure in NCI-H292 cells whether or not AG1478 was present (Figure 3d ). Nrf2 was constitutively activated, and in PC-9 cells, the degree of activation was not changed by CSE exposure (Figure 3d ). However, exposure to CSE reduced the inhibitory effects of AG1478 on Nrf2 activation (Figure 3d ). Activation of Nrf2 was not affected by CSE exposure in A549 cells (Figure 3d ). Keap1 levels were not altered by CSE exposure in any of the cell lines ( Figure 3d ).
Activation of Nrf2 by Keap1 knockdown enhances cell proliferation in Keap1 and EGFR wild-type NSCLC cells To assess directly the contribution of Keap1 to cancer cell proliferation, Keap1 mRNA was degraded with siRNA against Keap1 (Keap1-siRNA). We first confirmed that Keap1-siRNA efficaciously inhibited the expression of Keap1 in all NSCLC cells (Figure 4a ). Activation of Nrf2 was markedly increased in NCI-H292 cells by treatment with Keap1-siRNA ( Figure 4a ). Nrf2 was constitutively activated irrespective of the transfection of Keap1-siRNA in PC-9 cells and A549 cells (Figure 4a) .
We assessed the effect of Keap1 knockdown on cancer cell proliferation. The proliferation of NCI-H292 cells was significantly elevated by treatment with Keap1-siRNA, while the proliferation of PC-9 cells and A549 cells was not affected (Figure 4b ). The proliferation of NCI-H292 cells was slightly increased by treatment with Keap1-siRNA and EGF, while co-treatment with Keap1-siRNA and EGF did not affect the proliferation of PC-9 cells or A549 cells (Figure 4c ).
We then assessed the influence of Keap1 knockdown on the anticancer effect of EGFR-TKI. Transfection of Keap1-siRNA reduced the sensitivity of NCI-H292 cells to AG1478: cell proliferation was significantly higher in Keap1-siRNA-transfected NCI-H292 cells than in negative control siRNA (NC-siRNA)-transfected control under AG1478-treated conditions (Figure 4d ). PC-9 cell proliferation was also increased by transfection with Keap1-siRNA of AG1478-treated cells, compared with NC-siRNAtransfected controls, irrespective of EGF stimulation (Figure 4d ). Keap1-siRNA did not affect the sensitivity of A549 cells to AG1478 (Figure 4d ).
Detection of somatic mutation of Keap1 gene in a patient with EGFR-TKI-resistant NSCLC The present studies using NSCLC cell lines suggest that dysfunction of Nrf2-Keap1 interaction is a novel mechanism for resistance to EGFR-TKI. We therefore analyzed dysfunctional Keap1 gene mutation in patients with EGFR-TKI-resistant NSCLC, despite showing EGFR-TKI-sensitive EGFR gene mutations. We report the case of a 76-year-old woman with advanced NSCLC with metastatic brain and lung lesions (Figure 5a ). She received gefitinib, an EGFR-TKI, because a sensitive mutation (del E746-A750) was detected in the lung tumor specimen. Brain tumor mass was surgically resected to solve her symptoms. At 3 months after treatment with gefitinib, although pulmonary lesions disappeared, she was judged to have progressive disease because of the progression of carcinomatous meningitis diagnosed by brain magnetic resonance imaging and lumber puncture (Figure 5a ).
Immunohistochemistry of lung and brain tumor specimen showed strong immunoreactivity to Nrf2 in the brain tumor cells, but not in the lung tumor cells (Figure 5b) . Expression of NAD(P)H- quinone oxidoreductase 1 (NQO1), a detoxification enzyme, and multidrug resistance-associated protein 1, a drug efflux pump---known as the Nrf2-targeted molecules---was also observed in the brain lesions, but not in the lung lesions (Figure 5b ). Expression of Keap1 was detected in both brain and lung lesions (Figure 5b ). Sequencing analysis of the tumor genome DNA revealed a singlenucleotide mutation associated with amino-acid substitutions (GGC to AGC; G433S) in the Kelch domain of Keap1 in the brain tumor specimen, but detected no Keap1 gene mutation in the lung lesions ( Table 2 ). The deletion mutation of EGFR gene detected in the lung lesion was also observed in the brain lesion (Table 2) . No somatic mutations were detected in the KRAS genes either in brain or lung lesions.
DISCUSSION
Accumulating evidence suggests that Nrf2 plays an important role in cancer cell proliferation, so that Nrf2 is considered to be a new molecular target for the treatment of various cancers. In this study, we first demonstrated the mechanisms of Nrf2-mediated cancer cell proliferation using NSCLC cell lines that were selected based on their differences in Keap1 and EGFR genes. By sequencing analysis, NCI-H292 cells possess the wild-type EGFR and Keap1 genes. In these cells, activation of Nrf2 was dose-dependently enhanced by stimulation with an EGFR ligand, suggesting that the activation of Nrf2 was regulated by EGFR signaling during nonstress conditions in NSCLC cells and that their EGFR and Keap1 are functionally normal.
On the other hand, Nrf2 was constitutively activated in PC-9 cells and A549 cells without EGFR stimulation. We detected an inframe deletion mutation (del E746-A750) in exon 19 of the EGFR gene in PC-9 cells. This mutation is one of the major mutant forms of EGFR and is a determinant for responsiveness to EGFR-TKI, such as gefitinib and erlotinib. 12, 13 Previous studies using NSCLC cell lines have demonstrated that the cells possessing this type of mutation exhibit autodimerization and autophosphorylation of EGFR without any ligand stimulation.
14, 15 We also found that A549 cells do not have any mutation in the EGFR gene, but have disruption of Keap1-Nrf2 interactions in these cells. The finding that siRNA knockdown of Nrf2 inhibited cell proliferation of all NSCLC cells also suggests that Nrf2 is a pivotal factor for cancer cell proliferation as a downstream molecule of both EGFR signaling and Keap1-Nrf2 interaction. In this study, stimulation of NCI-H292 cells with EGFR ligand led to the phosphorylation of EGFR, ERK and Akt, as well as the activation of Nrf2. However, Nrf2 activation and cell proliferation was inhibited by treatment with inhibitors for EGFR-TKI or MEK1/2, but not PI3K, suggesting that Nrf2-mediated cell proliferation is mainly associated with the ERK pathway in these cells. These findings are reasonable as it is reported that, among the EGFR signaling pathways, the ERK pathway is a critically important route for regulating cancer cell proliferation and survival. 11 In PC-9 cells, cell proliferation was drastically reduced by treatment with EGFR-TKI, regardless of the presence of EGFR ligand. This finding is compatible with clinical cases and the experimental data in which NSCLC cells possessing this type of deletion mutation were highly susceptible to EGFR-TKI. 12, 13 Although both ERK and PI3K/Akt pathways were related to the proliferation of PC-9 cells, the inhibitor study demonstrated that the ERK pathway may more predominantly contribute to proliferation. The finding that constitutive activation of Nrf2 was also markedly inhibited by EGFR-TKI indicates that constitutive Nrf2 activation was also mediated by EGFR signaling in PC-9 cells.
The generation of reactive oxygen species during radiotherapy and chemotherapy can be exploited therapeutically in the treatment of cancer. However, it is also known that reactive oxygen species strongly activate Nrf2 via interactions with Keap1. 7, 8, 16 Cigarette smoke is known as a representative environmental inducer of oxidative stress. It has been demonstrated that exposure to CSE induces oxidative stress and causes activation of Nrf2 in lung cells. 17, 18 In this study, we demonstrated that although exposure to high concentrations of CSE inhibited cell proliferation, low concentrations of CSE enhanced NCI-H292 cell proliferation and Nrf2 activation. These findings suggest that low levels of oxidative stress enhance Nrf2-mediated cell proliferation in NSCLC cells whose EGFR gene and Keap1 genes are wild type. We also found that CSE and EGFR ligand additively enhanced the proliferation of these cells. Moreover, exposure to CSE decreased the anticancer effect of EGFR-TKI in these cells. These findings suggest that Nrf2-mediated cell proliferation is dually and independently regulated by EGFR signaling and interaction of Keap1-Nrf2 in NCI-H292 cells. Thus, low-level oxidative stress, possibly induced by cigarette smoke exposure and insufficient amounts of anticancer drugs, may increase resistance to EGFR-TKI as a result of the induction of Keap1-mediated Nrf2 activation. Supportively, we found that knock down of Keap1 also reduced the efficacy of EGFR-TKI in these cells.
As stated above, activating mutations in the EGFR-TK domain are a strong predictor for susceptibility to EGFR-TKI in NSCLC cells. 12, 13, 19 However, approximately 25% of NSCLC cells positive for EGFR mutations clinically show resistance to EGFR-TKI. 20, 21 Previous studies have reported that mutation of KRAS is associated with reduced response to EGFR-TKI. 22 The EGFR T790M mutation and MET gene amplification are also thought to be associated with acquired resistance to EGFR-TKI. 23 --25 In this study, interestingly, susceptibility to EGFR-TKI was attenuated by treatment with CSE or Keap1-siRNA in PC-9 cells. Thus, oxidative stress-induced Keap1-mediated activation of Nrf2, possibly caused by cigarette smoke exposure or treatment with insufficient amount of anticancer drugs, may reduce susceptibility to EGFR-TKI in NSCLC cells possessing a gefitinib-sensitive EGFR mutation. We also showed that A549 cells were highly resistant to EGFR-TKI. A549 cells exhibited strong constitutive activation of Nrf2 because of a dysfunctional mutation of the Keap1 gene. This finding suggests that dysfunction of the Keap1-Nrf2 interaction might be an additional molecular mechanism of intrinsic resistance to EGFR-TKI. A recent study demonstrated that Keap1 gene is inactivated not only by its somatic mutations, but also by methylation of the Keap1 gene promoter region in NSCLC cells. 26 Genetic and epigenetic abnormalities of the Keap1 gene should be evaluated to understand the dysfunction of Nrf2-Keap1 interaction in clinical cases.
In this study, we presented a case of advanced NSCLC possessing EGFR-TKI-sensitive EGFR gene mutation. In this case, although same EGFR gene mutation was detected in both the lung and brain specimen, EGFR-TKI was much effective for pulmonary lesions, but not for metastatic brain lesions. Interestingly, Keap1 gene mutation was detected only in the brain lesions. In the brain tumor cells, activation of Nrf2 was also observed with the induction of its targeted molecule NQO1 and multidrug resistance-associated protein 1. As with A549 cells, the mutation was located in the Kelch domain of Keap1 and was associated with amino-acid substitutions. It is therefore likely that the Keap1 gene mutation detected in the brain lesions is a dysfunctional mutation.
How tumor cells possessing Keap1 gene mutation emerge only in the metastatic brain lesions is a matter requiring further investigation. One hypothesis is that subclones bearing this mutation arise de novo at the site of metastasis. Other possibilities include that, like the evolution of imatinib-resistant clones of chronic myelogenous leukemia, 27 small populations of subclones bearing this mutation already exist in the primary tumor, and are grown predominantly at the site of metastasis. In either case, dysfunction of the Nrf2-Keap1 interaction is clinically important for acquiring resistance to EGFR-TKI in NSCLC having EGFR-TKIsensitive EGFR gene mutations. It should also be noted that a difference in redox conditions between the lung and the brain may explain increased Nrf2 activation in brain tumors.
Besides the Keap1 gene mutation, previous studies have demonstrated that A549 cells have a k-ras gene codon 12-point mutation. 28 This mutation causes resistance to EGFR-TKI because of aberrant Ras/ERK pro-growth signaling that occurs independently of EGFR phosphorylation. 29, 30 A recent study also demonstrated that cells expressing oncogenic allele of K-RAS activates Nrf2 via MAPK pathways in mouse embryonic fibroblasts. 31 However, we considered that constitutive activation of Nrf2 in A549 cells may be mainly due to dysfunction of Keap1, although Ras/ERK signaling partially contributes to the proliferation of these cells, as Nrf2 was still activated after treatment with U0126. Importantly, Nrf2 might be a useful therapeutic target for NSCLC cells having both KRAS and Keap1 mutations.
The molecular mechanisms of Nrf2-mediated cancer cell proliferation demonstrated in this study are schematically summarized in Figure 6 . In NSCLC cells having wild-type EGFR and Keap1 genes (Figure 6a : that is, NCI-H292 cells), Nrf2-mediated cell proliferation is dually regulated by EGFR signaling and Keap1/ Nrf2 interactions. In these cells, EGFR ligands dose-dependently activate Nrf2 and enhance cell proliferation. Oxidative and electrophilic stresses may also enhance cell proliferation through the reaction with Keap1, leading to a decline in Keap1-dependent ubiquitination of Nrf2. Although EGFR-TKI is partially effective at inhibiting cell proliferation, exposure to oxidative stress may attenuate the efficacy of EGFR-TKI. In NSCLC cells containing (Figure 6c : that is, PC-9 cells), Nrf2 is constitutively activated by autoactivation of EGFR signaling. In these cells, cell proliferation is largely dependent on the EGFR signaling pathway. Although these cells are highly sensitive to EGFR-TKI, exposure to oxidative stress may decrease the sensitivity of EGFR-TKI (Figure 6d ). Dysfunction of Keap1 might be an additional molecular mechanism of resistance to EGFR-TKI in these cells ( Figure 6d ). As shown in a case of NSCLC, Keap1 gene mutation may be clinically important for acquired resistance to EGFR-TKI ( Figure 5 ). Thus, analysis of Keap1 gene mutations may become a novel molecular marker to predict the efficacy of EGFR-TKI in NSCLC cells having EGFR-TKI-sensitive EGFR mutations. We reported previously, in systems other than cancer cell proliferation, that Nrf2 is essential for resistance to various anticancer drugs by transactivating a battery of self-defense genes, such as antioxidant enzymes, phase II detoxifying enzymes and drug efflux pumps in NSCLC cells. 5 It has clinically demonstrated that Nrf2 expression is associated with worse overall survival. 9 A recent study has demonstrated that inhibition of the Nrf2 pathway enhanced the efficacy of chemotherapy. 32 We emphasize that Nrf2 is a critical molecular target for therapeutics of NSCLC cells to improve sensitivity to both EGFR-TKI and other carcinostatics. Moreover, inactivation of Nrf2 may be useful in NSCLC cells having EGFR-TKI-resistant mutations, such as the KRAS mutation, and Keap1 mutations.
MATERIALS AND METHODS

Cells lines and tissue samples
Human NSCLC cell lines A549 cells were obtained from Riken BioResource Center (Ibaraki, Japan). NCI-H292 cells were obtained from American Type Culture Collection (Manassas, VA, USA). PC-9 cells were obtained from IBL Co., Ltd (Gumma, Japan). These cells were cultivated in RPMI1640 medium containing 10% fetal bovine serum (Nichirei, Tokyo, Japan). Cultures were maintained in 5% CO 2 and air humidified in a 37 1C incubator. Formalinfixed paraffin-embedded lung tumors and metastatic brain tumors were used for immunostaining and isolation of DNA. The use of all clinical materials mentioned was approved by individual institutional ethics committees.
Western blotting
Nuclear fractions were prepared using a Nuclear Extraction Kit (Panomics, Redwood City, CA, USA) according to the manufacturer's protocol. To prepare whole cell lysates, cells were lysed with radioimmunoprecipitation assay buffer (10 mM Tris, 1% Triton, 1% Na deoxycholate, 0.1% sodium dodecylsulfate, 150 mM NaCl, 5 mM EDTA, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 2 mM phenylmethanesulfonylfluoride, 1 mM Na 3 VO 4 , 1mM NaF). The protein concentration was determined by a BCA protein-assay kit (Biorad, Hercules, CA, USA). Proteins in nuclear fractions and cell lysates were separated on 5 --15% gradient SDS --polyacrylamide gels and transferred onto a polyvinylidene difluoride membrane. The membrane was stained immunochemically using anti-Nrf2, Keap1, EGFR, p-EGFR, ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-ERK1/2, AKT and p-AKT antibodies (Cell Signaling Technology, Danvers, MA, USA). Immunoreactive bands were detected using ECL western blotting detection reagents (Amersham, Buckinghamshire, UK).
Immunohistochemistry
Cancer cells were plated in 10 cm 2 dishes, in which collagen-coated glass slides were tiled. After treatment with human recombinant EGF (Invitrogen, Carlsbad, CA, USA) or vehicle, the cells were fixed and stained immunohistochemically using anti-Nrf2 and anti-Keap1 antibodies (Santa Cruz Biotechnology). Formalin-fixed paraffin-embedded tumor specimen was also stained with anti-Nrf2, anti-NQO1 (Abcam, Cambridge, UK), and anti-MRP 1 (Abcam). Diaminobenzidine was used as a chromogen.
Cigarette smoke extract CSE was prepared by bubbling smoke from one cigarette (High Lite; Japan Tobacco Inc., Tokyo, Japan) into 10 ml of RPMI 1640 media at a rate of one cigarette per 2 min as described previously. 33 This CSE solution was filtered for sterilization through a 0.22 mm pore filter (Millipore, Billerica, MA, USA). CSE was standardized by measuring the absorbance at 320 nm. The prepared CSE was defined as 100% CSE and diluted with serum-free RPMI 1640 before use.
Transfection of siRNA
The Nrf2-siRNA, human Keap1 (Keap1-siRNA) and their non-targeting NCsiRNAs were purchased from Invitrogen. Cancer cells were transfected with these siRNAs using the Lipofectamine RNAi Max (Invitrogen) according to the manufacturer's protocol. The final concentration of the siRNAs was 20 nmol/l. 
